http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017506250-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-664 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate | 2015-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017506250-A |
| titleOfInvention | Pyrazolo [1,5-A] pyrimidine-5,7-diamine compounds as CDK inhibitors and therapeutic uses thereof |
| abstract | The present invention relates generally to the field of therapeutic compounds. More particularly, the present invention relates to certain pyrazolo [1,5-a] pyrimidine-5,7-diamine compounds (referred to herein as “PPDA compounds”), which are notably CDKs. (For example, selectively inhibit) CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc. The invention also relates to pharmaceutical compositions comprising such compounds, and uses of such compounds and compositions to inhibit CDK both in vitro and in vivo and to treat disorders. This disorder includes CDK-related disorders; disorders caused by inappropriate activity of cyclin-dependent kinases (CDKs); disorders associated with CDK mutations; disorders associated with CDK overexpression; Disorders that ameliorate by inhibiting CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischemia; kidney disease; and cardiovascular disorders ( Including atherosclerosis). Optionally, the treatment described above further comprises treatment with additional active agents (eg, simultaneous treatment or sequential treatment), wherein the additional active agents are, for example, aromatase inhibitors, antiestrogens, Her2 blockers, cytotoxicity Sex chemotherapeutic agents. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200070323-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020534346-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021521120-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102450727-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7148604-B2 |
| priorityDate | 2014-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 717.